Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

158 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone.
Desikan KR, Tricot G, Dhodapkar M, Fassas A, Siegel D, Vesole DH, Jagannath S, Singhal S, Mehta J, Spoon D, Anaissie E, Barlogie B, Munshi N. Desikan KR, et al. Among authors: fassas a. Bone Marrow Transplant. 2000 Mar;25(5):483-7. doi: 10.1038/sj.bmt.1702167. Bone Marrow Transplant. 2000. PMID: 10713623 Clinical Trial.
Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities.
Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A, Zangari M, Munshi NC, Anaissie E, Spoon D, Siegel D, Jagannath S, Vesole D, Epstein J, Shaughnessy J, Fassas A, Lim S, Roberson P, Crowley J. Desikan R, et al. Among authors: fassas a. Blood. 2000 Jun 15;95(12):4008-10. Blood. 2000. PMID: 10845942 Free article. Clinical Trial.
High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions.
Badros A, Barlogie B, Morris C, Desikan R, Martin SR, Munshi N, Zangari M, Mehta J, Toor A, Cottler-Fox M, Fassas A, Anaissie E, Schichman S, Tricot G. Badros A, et al. Among authors: fassas a. Blood. 2001 May 1;97(9):2574-9. doi: 10.1182/blood.v97.9.2574. Blood. 2001. PMID: 11313244 Free article. Clinical Trial.
Thalidomide in the management of multiple myeloma.
Barlogie B, Zangari M, Spencer T, Fassas A, Anaissie E, Badros A, Cromer J, Tricot G. Barlogie B, et al. Among authors: fassas a. Semin Hematol. 2001 Jul;38(3):250-9. doi: 10.1016/s0037-1963(01)90017-4. Semin Hematol. 2001. PMID: 11486313 Review.
Results of autologous stem cell transplant in multiple myeloma patients with renal failure.
Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M, Desikan R, Shaver MJ, Fassas A, McConnell S, Muwalla F, Barri Y, Anaissie E, Munshi N, Tricot G. Badros A, et al. Among authors: fassas a. Br J Haematol. 2001 Sep;114(4):822-9. doi: 10.1046/j.1365-2141.2001.03033.x. Br J Haematol. 2001. PMID: 11564069 Free article.
158 results